Table 2.
Details and outcomes of patients with contralateral lobe PTC
| Patient | Multifocality Status | Time to Contralateral Lobe PTC* (years) | Management of Contralateral Lobe PTC | Final Outcome - ATA† response to treatment |
|---|---|---|---|---|
| 1 | MFD‡ | 1.1 | Surgery | NED‖ - Unknown |
| 2 | UFD§ | 1.3 | Surgery | NED - Excellent |
| 3 | UFD | 3.0 | Surgery | NED - Unknown |
| 4 | UFD | 3.0 | Surgery | NED - Excellent |
| 5 | UFD | 3.5 | Surgery | NED - Unknown |
| 6 | UFD | 4.9 | Surgery | NED - Unknown |
| 7 | UFD | 6.1 | Surgery | NED - Unknown |
| 8 | MFD | 10.6 | Surgery | NED - Excellent |
| 9 | UFD | 11.3 | Surgery | NED - Indeterminate |
| 10 | MFD | 11.9 | Surgery | NED - Unknown |
| 11 | UFD | 12.9 | Surgery | NED - Indeterminate |
| 12 | MFD | 13.3 | Active Surveillance | ALD¶ - Structural Incomplete |
| 13 | UFD | 13.5 | Active Surveillance | ALD - Structural Incomplete |
| 14 | MFD | 23.5 | Surgery | NED - Indeterminate |
PTC – Papillary Thyroid Carcinoma
ATA – American Thyroid Association
MFD – multifocal disease
UFD – unifocal disease
NED – no evidence of disease
ALD – alive with loco-regional disease